Evidence map›Paper›PMID 39125457›Full record

ArticleDiagnostics (Basel, Switzerland)2024

The Importance of the Type of Posterior Staphyloma in the Development of Myopic Maculopathy.

Jorge Ruiz-Medrano, Mariluz Puertas, Ignacio Flores-Moreno, Elena Almazán-Alonso, María García-Zamora, Bachar Kudsieh, José M Ruiz-Moreno

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jorge Ruiz-MedranoPuerta de Hierro-Majadahonda University Hospital, C/Manuel de Falla, 1, 28222 Madrid, Spain.ORCID 0000-0002-1105-9265
Mariluz PuertasPuerta de Hierro-Majadahonda University Hospital, C/Manuel de Falla, 1, 28222 Madrid, Spain.ORCID 0000-0001-5557-6822
Ignacio Flores-MorenoPuerta de Hierro-Majadahonda University Hospital, C/Manuel de Falla, 1, 28222 Madrid, Spain.ORCID 0000-0003-4236-514X
Elena Almazán-AlonsoPuerta de Hierro-Majadahonda University Hospital, C/Manuel de Falla, 1, 28222 Madrid, Spain.
María García-ZamoraPuerta de Hierro-Majadahonda University Hospital, C/Manuel de Falla, 1, 28222 Madrid, Spain.ORCID 0000-0003-3716-4992
Bachar KudsiehPuerta de Hierro-Majadahonda University Hospital, C/Manuel de Falla, 1, 28222 Madrid, Spain.
José M Ruiz-MorenoPuerta de Hierro-Majadahonda University Hospital, C/Manuel de Falla, 1, 28222 Madrid, Spain.ORCID 0000-0001-9636-0788

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this paper was to determine how different types of posterior staphyloma (PS) may affect the appearance and degree of myopic maculopathy. A cross-sectional study was conducted, in which 467 eyes from 246 highly myopic patients [axial length (AL) ≥ 26 mm] were studied. A complete ophthalmic exploration was carried out on all patients, including imaging tests. The presence of macular PS was established as the main comparison variable between groups (macular PS vs. non-macular PS vs. non-PS). The variables analyzed included age, AL, decimal best-corrected visual acuity (BCVA), Atrophy (A)/Traction (T)/Neovascularization (N) components according to the ATN grading system, and the presence of severe pathologic myopia (PM). Out of the total, 179 eyes (38.3%) presented macular PS, 146 eyes presented non-macular PS (31.2%), and 142 eyes showed no PS (30.4%). The group without PS was significantly younger than macular PS and non-macular PS groups (53.85 vs. 66.57 vs. 65.20 years;

Indexed as

ATNmyopic maculopathypathologic myopiaposterior staphyloma

Identifiers

PMID39125457
PMCPMC11311493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.